Related Experiment Video
Updated: Jun 6, 2026
09:53
In vivo Imaging of Transgenic Leishmania Parasites in a Live Host
Published on: July 27, 2010
Toll-like receptor 4 polymorphisms predispose to cutaneous leishmaniasis
Soheila Ajdary1, Mir-Mostafa Ghamilouie, Mohammad-Hossein Alimohammadian
1Immunology Department, Pasteur Institute of Iran, Pasteur Ave., Tehran, Islamic Republic of Iran. sohary@yahoo.com
Microbes and Infection
|November 9, 2010
Summary
Toll-like receptor 4 (TLR4) gene mutations are linked to increased susceptibility and severity of cutaneous leishmaniasis (CL). Specific TLR4 variants, Asp299Gly and Thr399Ile, were found more frequently in patients with acute and chronic CL, indicating a role in disease outcome.
Area of Science:
- Immunogenetics
- Infectious Diseases
- Dermatology
Background:
- Cutaneous leishmaniasis (CL) presents with highly variable clinical manifestations.
- Toll-like receptor 4 (TLR4) has been implicated in controlling leishmaniasis infections in experimental models.
Purpose of the Study:
- To investigate the association between specific Toll-like receptor 4 (TLR4) gene mutations (Asp299Gly and Thr399Ile) and the clinical outcome of cutaneous leishmaniasis (CL).
Main Methods:
- Genotyping was performed for TLR4 Asp299Gly and Thr399Ile mutations in patients with chronic CL (N=22), acute CL (N=61), asymptomatic individuals (N=45), and healthy controls (N=75).
- Statistical analysis, including odds ratios (OR) and p-values, was used to compare genotype frequencies between groups.
Main Results:
- The Asp299Gly genotype was significantly more frequent in patients with chronic CL (OR 25.3) and acute CL (OR 8.03) compared to healthy controls.
- The Thr399Ile genotype was overrepresented in patients with chronic CL (27.3%), acute CL (13.1%), and asymptomatic individuals (15.6%) versus healthy controls (1.3%).
- Concomitant carriage of both TLR4 mutations was more frequent in chronic CL patients than in acute CL or asymptomatic individuals.
Conclusions:
- Polymorphisms in the TLR4 gene are associated with increased susceptibility to and severity of Leishmania major infection, leading to CL.
- The presence of both Asp299Gly and Thr399Ile mutations in the TLR4 gene exacerbates an individual's susceptibility to cutaneous leishmaniasis.
More Related Videos
Related Concept Videos
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:26Rocky Mountain Spotted Fever
Rocky Mountain Spotted Fever (RMSF) is a severe tick-borne illness caused by Rickettsia rickettsii, a Gram-negative, coccobacillary bacterium. This pathogen is an obligate intracellular parasite, requiring a host cell for replication. Transmission occurs through the bite of an infected tick. In the United States, the most important vectors are Dermacentor variabilis (American dog tick) and Dermacentor andersoni (Rocky Mountain wood tick), though other tick species may also serve as vectors.